Pfizer drops India vaccine application after regulator seeks local trial (Feb 5 2021)¶
Pfizer drops India vaccine application after regulator seeks local trial¶
<p><a href=”https://news.yahoo.com/exclusive-pfizer-withdraws-application-emergency-052857135.html” target=”_blank” rel=”noopener noreferrer”>Pfizer drops India vaccine application after regulator seeks local trial</a>.</p>
Date: Fri, February 5, 2021, 12:28 AM
By Krishna N. Das
NEW DELHI (Reuters) - Pfizer Inc said on Friday it had withdrawn an application for emergency-use authorisation of its COVID-19 vaccine in India, after failing to meet the drug regulator’s demand for a local safety and immunogenicity study.
The decision means the vaccine will not be available for sale in the world’s two most populous countries, India and China, in the near future. Both countries are running their immunisation campaigns using other products.
Krishna N. Das Fri, February 5, 2021, 12:28 AM By Krishna N. Das
NEW DELHI (Reuters) - Pfizer Inc said on Friday it had withdrawn an application for emergency-use authorisation of its COVID-19 vaccine in India, after failing to meet the drug regulator’s demand for a local safety and immunogenicity study.
The decision means the vaccine will not be available for sale in the world’s two most populous countries, India and China, in the near future. Both countries are running their immunisation campaigns using other products.
Unlike other companies conducting small studies in India for foreign-developed vaccines, Pfizer had sought an exception citing approvals it had received elsewhere based on trials done in countries such as the United States and Germany.
Bridging trials are used to determine if a vaccine is safe and generates an immune response¶
Indian health officials say they generally ask for so-called bridging trials to determine if a vaccine is safe and generates an immune response in its citizens. There are, however, provisions under India’s rules to waive such trials in certain conditions.
Pfizer declines to perform a Bridging trial¶
The drug regulator said on its website its experts did not recommend the vaccine because of side effects reported abroad were still being investigated. It also said Pfizer had not proposed any plan to generate safety and immunogenicity data in India.
Last change: Tue, 03 Aug 2021 10:25 PM UTC